OTCM
LVGI
Market cap288kUSD
Jul 08, Last price
0.00USD
1D
0.00%
1Q
0.00%
Jan 2017
-99.56%
IPO
-100.00%
Name
Limitless Venture Group Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
126.83%
Rev. gr., 5y
%
Revenues
0k
-100.00%
Net income
-644k
L-47.93%
CFO
-24k
L-76.27%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Limitless Venture Group Inc. (LVGI), currently operating as a development stage enterprise, specializes in the production, distribution, and sale of an extensive portfolio encompassing personal care items, health supplements, and alcoholic beverages. Within its LIMITLESS BODY collection, consumers can find products like BODY FRESH body wash, MUSCLE BUTTER soothing massage butter, BODY SUGAR scrub, BARE SKIN moisturizing shave cream, and GYM SANI-T sanitizer. The company's LIMITLESS HEALTH division offers supplements such as Prostaderol for prostate well-being, LipiRestorin, and Maxtlevelin, designed to boost testosterone levels. Additionally, through its HempCore health product line, LVGI provides RELAX for anxiety relief, FIBER UP for detoxification, HEALTHY HEART to support cardiovascular health and manage cholesterol, BRAIN BOOST to optimize neurotransmitter activity and nutrient flow to the brain, and JOINT RELEIF, an anti-inflammatory formula for joint restoration, lubrication, and comfort. The firm also crafts a range of ready-to-drink alcoholic shots, including Haymaker (vodka with lemon and tea), CoCo-Puff (vodka with chocolate and Irish cream), Red Headed Slut (vodka with peach, licorice, and cranberry), Twist (tequila with lime), and Kamikaze (vodka with orange liquor and lime). Initially established as Enerbrite Technologies Group Inc., the organization adopted its current name, Limitless Venture Group Inc., in February 2013 and is headquartered in Tulsa, Oklahoma.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑06 | 2018‑06 | 2017‑06 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||